Moderna Publishes Positive Phase 3 Clinical Data for mRNA-1010 Seasonal Influenza Vaccine in New England Journal of Medicine
CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...
Bagsværd, Denmark – April 23, 2026 In a major advancement for pediatric diabetes care, Novo Nordisk announced positive Phase...
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
TAMPA, Fla., March 30, 2026 Concept Medical Inc. (CMI) announced the primary results of the SirPAD randomized controlled trial,...
Cambridge, Massachusetts, March 16, 2026 NeuroSense Therapeutics Ltd. announced the publication of results from its PARADIGM Phase 2b clinical...
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
Horsham, Pa., Sept. 29, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for TREMFYA® (guselkumab)...
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
